“…Although NSAIDs inhibit both COX isoforms, selective inhibition of COX-2 results in decreased prostacyclin, a vasodilator and moderator of platelet activation, without reducing COX-1-dependent thromboxanes, contributors to platelet aggregation and vasoconstriction. 21,22 Emerging data support a varied role for COX-2 in the vascular bed, with important functions in vascular resistance, 23 late preconditioning, 24 endothelial function, 25,26 and atherogenesis. 27,28 Data from rat models of hypertension suggest that celecoxib may be associated with improvements in endothelial function and reductions in oxidative stress 29 ; neutral findings have been reported for rofecoxib and diclofenac.…”